# CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

> **NCT03448393** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 54 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Leukemia, Lymphocytic, B Cell
- B-Cell Lymphoma
- B-Cell Leukemia
- Acute Lymphoid Leukemia
- B-Non Hodgkin Lymphoma
- B-NHL
- B-All
- Acute Lymphoblastic Leukemia
- Acute Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** CD19/CD22 CAR T-Cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Apheresis
- **OTHER:** Anti-emetic
- **DRUG:** Diphenhydramine
- **DRUG:** Acetaminophen
- **DIAGNOSTIC_TEST:** ECG
- **DIAGNOSTIC_TEST:** ECHO
- **DIAGNOSTIC_TEST:** MRI Brain
- **PROCEDURE:** Bone marrow biopsy
- **DIAGNOSTIC_TEST:** Cardiac MRI

## Key facts

- **NCT ID:** NCT03448393
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-26
- **Primary completion:** 2024-07-10
- **Final completion:** 2025-01-13
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03448393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03448393, "CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03448393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*